Cidara Therapeutics Inc Stock
Price
Target price
-
-
-
-
-
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Cidara Therapeutics Inc Stock
For the coming years our community has positive and negative things to say abot the Cidara Therapeutics Inc stock. Criterium "Revenue growth" gathered the most positive votes but regarding "Company culture" there were negative voices in the community.
Pros and Cons of Cidara Therapeutics Inc in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cidara Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cidara Therapeutics Inc | - | - | - | - | - | - | - |
| Vaxart Inc. | 0.000% | 0.000% | 74.377% | -29.242% | 75.000% | -50.415% | -95.025% |
| Larimar Therapeutics Inc. | -2.010% | 2.740% | -8.537% | -14.286% | -9.639% | -26.108% | -76.378% |
| aTyr Pharma Inc | -19.310% | 0.000% | -3.333% | -82.317% | -3.333% | -72.744% | -79.433% |
Comments
News
Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?
According to a November 14, 2025 SEC filing, HighVista Strategies LLC initiated a new stake in Cidara Therapeutics (NASDAQ:CDTX), acquiring 70,904 shares worth $6.79 million as of September 30
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer
On November 14, 2025, Bain Capital Life Sciences Investors, LLC disclosed a purchase of 520,310 shares of Cidara Therapeutics (NASDAQ:CDTX), increasing its position value by approximately $167.48
Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.
Just prior to last week's takeover news, Cidara Therapeutics (NASDAQ: CDTX) was already one of the year's top-performing stocks. Trading in the mid-$20s at the start of 2025, by mid-November, this